Advocacy intelligence hub — real-time data for patient organizations
VA Office of Research and Development — PHASE3
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences — PHASE2
University of Stirling — NA
Sanofi — PHASE4
Incyte Corporation — PHASE2
Universitas Katolik Widya Mandala Surabaya — NA
Selcuk University
Hôpital Fribourgeois — NA
M.D. Anderson Cancer Center
Apellis Pharmaceuticals, Inc. — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
NIKTIMVO
Incyte
Patient Assistance Programs1
Orencia
Bristol-Myers Squibb Co.
Niktimvo
(axatilimab-csfr)Orphan drugIncyte Corporation
Colony Stimulating Factor-1 Receptor Blocker [EPC]
12.1 Mechanism of Action Axatilimab-csfr is a monoclonal antibody that binds to colony stimulating factor-1 receptors (CSF-1R) expressed on monocytes ...
IMBRUVICA
(ibrutinib)Orphan drugstandardPharmacyclics, LLC
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine re...
Rezurock
(belumosudil)Orphan drugstandardKadmon Pharmaceuticals, LLC
12.1 Mechanism of Action Belumosudil is an inhibitor of rho-associated, coiled-coil containing protein kinase (ROCK) which inhibits ROCK2 and ROCK1 wi...
JAKAFI
(RUXOLITINIB)Orphan drugstandardIncyte Corporation
Emerging strategies for the prevention and management of chronic graft-versus-host disease.
Chronic graft-versus-host disease remains a major cause of late morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Conventional prevention and management strategies, hea...
Evolving Paradigms in Chronic Graft-Versus-Host Disease: From Global Immunosuppression to Precision Targeted and Cell-Based Therapies.
Evolving Paradigms in Chronic Graft-Versus-Host Disease: From Global Immunosuppression to Precision Targeted and Cell-Based Therapies.
Belumosudil for Chronic Graft-Versus-Host Disease: A Systematic Review and Meta-Analysis.
Chronic graft-versus-host disease (cGvHD) is a debilitating complication following allogeneic hematopoietic stem cell transplantation, often refractory to standard therapies. Belumosudil, a selective ...
Toward Better and More Effective Clinical Trials for Chronic Graft-Versus-Host Disease.
While the incidence of chronic Graft-versus-Host Disease (chronic GVHD) is declining due to advances in prophylaxis and survival is improving due to better supportive care, first-line treatment of chr...
Chronic graft-versus-host disease: Current situation and unmet needs - A European position statement.
Chronic graft-versus-host disease (cGVHD) remains the leading cause of late morbidity and non-relapse mortality after allogeneic hematopoietic cell transplantation, despite major advances in transplan...
Linezolid-mediated Prevention of Fibroblast Activation and Tissue Fibrosis via Mitochondrial Translation Inhibition.
Beyond its role as a ribosome-targeting antibiotic, linezolid was recently shown to modulate immune responses by inhibiting mitochondrial translation. Because mitochondrial dysfunction is implicated i...
Rubén Cuesta-Barriuso, PhD
Universidad de Oviedo
Frédérique Menzaghi, PhD
Cara Therapeutics
Nicholas S Hill, MD
Tufts Medical Center
Kenneth Peters, MD
Corewell Health East
Neha Sharma
Aarogyam UK
Andrew Zelenetz, MD, PhD, MD
Memorial Sloan Kettering Cancer Center
📍 NEW YORK, NY